Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.58 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.58 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.58 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.58 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27431285 | 0.95 | MAPT (0.58) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL2222140 | 0.93 | HDAC1 (0.67) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL4606935 | 0.91 | HDAC1 (0.56) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL17223648 | 0.91 | HDAC1 (0.64) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL27825851 | 0.90 | HDAC1 (0.55) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL1739442 | 0.89 | TDP1 (0.63) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL7431738 | 0.89 | TDP1 (0.63) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL13498527 | 0.89 | MAPT (0.63) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL28829454 | 0.87 | TDP1 (0.61) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL8790943 | 0.87 | MAPT (0.66) | HDAC1HDAC3HDAC2HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110337442-B | Novel glucose derivatives as inhibitors of sodium-dependent glucose transporter type 2 | 东亚ST株式会社 | 2023-05-12 | — | — | CN | disclosed |
| US-11357748-B2 | Methods for treating mendelian disorders of the epigenetic machinery | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-06-14 | — | — | US | disclosed |
| US-10568854-B2 | Compositions and methods for treating kabuki syndrome and related disorders | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-02-25 | — | — | US | disclosed |
| CN-109715721-A | Resin combination and resin-formed body | 富士施乐株式会社 | 2019-05-03 | — | — | CN | disclosed |
| US-20170100354-A1 | COMPOSITIONS AND METHODS FOR TREATING KABUKI SYNDROME AND RELATED DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-04-13 | — | — | US | disclosed |
| US-20170095436-A1 | METHODS FOR TREATING MENDELIAN DISORDERS OF THE EPIGENETIC MACHINERY | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-04-06 | — | — | US | disclosed |
| WO-2015184279-A1 | COMPOSITIONS AND METHODS FOR TREATING KABUKI SYNDROME AND RELATED DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-12-03 | — | — | WO | disclosed |
| WO-2015184260-A2 | METHODS FOR TREATING MENDELIAN DISORDERS OF THE EPIGENETIC MACHINERY | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-12-03 | — | — | WO | disclosed |
| US-20120108522-A1 | HDAC INHIBITORS AND HORMONE TARGETED DRUGS FOR THE TREATMENT OF CANCER | UNIVERSITY OF MARYLAND, BALTIMORE | 2012-05-03 | — | — | US | disclosed |
| US-8110550-B2 | HDAC inhibitors and hormone targeted drugs for the treatment of cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2012-02-07 | — | — | US | disclosed |
| EP-2359828-A1 | HDAC inhibitors and hormone targeted drugs for the treatment of cancer | University of Maryland, Baltimore (US) | 2011-08-24 | — | — | EP | disclosed |
| EP-2167090-A2 | HDAC INHIBITORS AND HORMONE TARGETED DRUGS FOR THE TREATMENT OF CANCER | University of Maryland, Baltimore (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090048156-A1 | HDAC INHIBITORS AND HORMONE TARGETED DRUGS FOR THE TREATMENT OF CANCER | UNIVERSITY OF MARYLAND, BALTIMORE | 2009-02-19 | — | — | US | disclosed |
| WO-2008154402-A2 | HDAC INHIBITORS AND HORMONE TARGETED DRUGS FOR THE TREATMENT OF CANCER | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2008-12-18 | — | — | WO | disclosed |
| CN-1003124-B | Method for synthesizing ben butyl propylprolic acid | 国家医药管理局上海医药工业研究院 | 1989-01-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108522-A1 | HDAC INHIBITORS AND HORMONE TARGETED DRUGS FOR THE TREATMENT OF CANCER | HDAC5, HDAC1, HDAC4 | HDAC1 2/4885HDAC3 4/4885HDAC2 6/4885 |
| US-20090048156-A1 | HDAC INHIBITORS AND HORMONE TARGETED DRUGS FOR THE TREATMENT OF CANCER | HDAC5, HDAC1, HDAC4 | HDAC1 2/4885HDAC3 4/4885HDAC2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.